Tempus AI is a very competent investment opportunity for long-term investors in the growing field of precision medicine using ...

Stifel has downgraded Tempus AI (NASDAQ:TEM) to hold from buy, citing valuation and uncertainty about core growth in 2025.

The firms said that the deal will provide access to Tempus' testing menu for healthcare providers at 800 cancer care locations that use Flatiron's OncoEMR platform.

Aliso Viejo-based Ambry Genetics Corp. on Nov. 4 announced an agreement to be acquired for $600 million by Tempus AI Inc.

Stifel Nicolaus analyst Daniel Arias downgraded the rating on Tempus AI, Inc. Class A (TEM – Research Report) to a Hold yesterday, ...

With Ambry Genetics in tow, Eric Lefkofsky's biotech startup hopes to accelerate its drive toward turning a profit.

Fintel reports that on November 11, 2024, Stifel downgraded their outlook for Tempus AI (NasdaqGS:TEM) from Buy to Hold. ...

The firm's Q3 2024 revenues rose 33 percent year over year as both its genomics and data and services revenues increased in the double-digit percent range.

Tempus announced that it has entered into an agreement to acquire Ambry Genetics, a leader in genetic testing. Under the terms of the ...

Aliso Viejo-based Ambrey Genetics Corp., Orange County’s third-largest medical diagnostics and testing company, has entered ...

Tempus AI said it agreed to pay $375 million in cash and $225 million in shares to acquire genetic testing company Ambry Genetics. Ambry conducts hereditary cancer screening and currently serves as ...

Acquisition Multiples: 1.9 times current revenue and roughly 15 times EBITDA. Tempus AI Inc (NASDAQ:TEM) reported a 33% revenue growth, reaching $180.9 million for Q3 2024. The company's data and ...